MCID: MLG071
MIFTS: 11

Malignant Leptomeningeal Tumor

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Malignant Leptomeningeal Tumor

MalaCards integrated aliases for Malignant Leptomeningeal Tumor:

Name: Malignant Leptomeningeal Tumor 12 15
Malignant Leptomeningeal Neoplasm 73
Malignant Tumor of Leptomeninges 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6086
NCIt 50 C8506
UMLS 73 C1334596

Summaries for Malignant Leptomeningeal Tumor

MalaCards based summary : Malignant Leptomeningeal Tumor, is also known as malignant leptomeningeal neoplasm. An important gene associated with Malignant Leptomeningeal Tumor is MITF (Melanogenesis Associated Transcription Factor). The drugs Iodine and Dexamethasone have been mentioned in the context of this disorder.

Related Diseases for Malignant Leptomeningeal Tumor

Symptoms & Phenotypes for Malignant Leptomeningeal Tumor

Drugs & Therapeutics for Malignant Leptomeningeal Tumor

Drugs for Malignant Leptomeningeal Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 15)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 2,Phase 1 7553-56-2 807
2
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
3
Acetaminophen Approved Phase 2 103-90-2 1983
4
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
5
Promethazine Approved, Investigational Phase 2 60-87-7 4927
6 cadexomer iodine Phase 2,Phase 1
7 Antibodies Phase 2,Phase 1
8 Immunoglobulins Phase 2,Phase 1
9 Antibodies, Monoclonal Phase 2,Phase 1
10 Dexamethasone acetate Phase 2 1177-87-3
11 Micronutrients Phase 2
12 Trace Elements Phase 2
13 Anti-Infective Agents Phase 2
14 Anti-Infective Agents, Local Phase 2
15 BB 1101 Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
2 Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer Completed NCT00003022 Phase 1
3 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer Recruiting NCT00089245 Phase 1

Search NIH Clinical Center for Malignant Leptomeningeal Tumor

Genetic Tests for Malignant Leptomeningeal Tumor

Anatomical Context for Malignant Leptomeningeal Tumor

Publications for Malignant Leptomeningeal Tumor

Variations for Malignant Leptomeningeal Tumor

Expression for Malignant Leptomeningeal Tumor

Search GEO for disease gene expression data for Malignant Leptomeningeal Tumor.

Pathways for Malignant Leptomeningeal Tumor

GO Terms for Malignant Leptomeningeal Tumor

Sources for Malignant Leptomeningeal Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....